•Hospitalization, ICU admission, and mortality among diabetic patients with inflammatory bowel disease receiving SGLT-2 inhibitors: a retrospective cohort study from the global collaborative network
•Increased risk of de novo inflammatory bowel disease following cholecystectomy: a population-based analysis
•Blood eosinophilia in patients with inflammatory bowel disease losing response to biologics
•Intestinal cancer risk in Crohn's disease: authors' reply on methods, data integrity, and clinical implications
•Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs
